Hong Kong stocks surged | Kingway Pharmaceutical-B (02595.HK) rose over 15% in the morning to announce the completion of the first case in the overseas Phase II PDAC study of GFH375/VS-7375.

Zhitong Finance and Economics App learned that Jingfang Pharmaceuticals-B (02595.HK) surged more than 15% in the morning, and as of the press time, it increased by 15.64% to 28.1 Hong Kong dollars, with a turnover of 328.91 million Hong Kong dollars.